UNSPSC 51373308: Acetaminophen/caffeine/codeine/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51373308 Acetaminophen/caffeine/codeine/salicylamide is a Commodity code that state and local governments use to procure pharmaceutical products and drug-related health supplies, though recent solicitations tagged to this code show significant scope divergence. The most recent opportunities include naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products — a broader range than the specific combination compound the code nominally describes. Issuing bodies soliciting under this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating state and local government facilities across multiple jurisdictions including Oregon). The work typically involves establishing supply agreements for medications and related health products distributed through authorized wholesalers or direct delivery to county health facilities, with vendors required to comply with FDA manufacturing standards, Drug Supply Chain Security Act requirements, and state workforce verification mandates.

Recent activity concentrates in Texas and Florida, with multistate cooperative procurement agreements spanning the upper Midwest and Pacific Northwest. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission released an RFI on April 3, 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendor capabilities for direct contracting with self-insured health plans and state agencies outside traditional pharmacy benefit manager arrangements. Minnesota's MMCAP issued an RFP posted January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with award effective July 1, 2026 and a two-year contract term. Vendors typically bear shipping and delivery costs, must maintain specific insurance coverages including commercial general liability between $2,000,000 and $5,000,000 per occurrence, and face performance penalties of $200 to $1,500 per violation for reporting or onboarding failures.